A phase I/II study of docetaxel and epirubicin as first line therapy for metastatic breast cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Docetaxel; Epirubicin; Filgrastim
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 01 Apr 2020 Biomarkers information updated
- 08 Nov 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 08 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.